Skip to content
Open in App
ABPRO Holdings logo

ABPRO Holdings

web2

Abpro Holdings is a clinical-stage biotechnology company developing engineered antibody therapi...

Symbol ยท ABPO
Company profile

About

Abpro Holdings is a clinical-stage biotechnology company developing engineered antibody therapies for cancer and eye diseases using proprietary antibody discovery and design platforms. The company's DiversImmune and MultiMab technologies help it identify and engineer antibodies that bind selected disease targets. Its ABP-102 candidate is designed to direct immune cells against tumors expressing HER2 and is being evaluated in early clinical development with Celltrion. Another candidate, ABP-201, targets pathways involved in abnormal blood vessel growth in eye disease. Abpro develops its pipeline through internal research and partnerships with pharmaceutical companies, and its therapies remain investigational rather than approved commercial medicines.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeOTC MarketsPrimary symbol: ABPO
Expert coverage

ABPRO Holdings profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment